



FOR IMMEDIATE RELEASE

Contact:
Susan Brady
Corporate Communications
617.621.8304
sbrady@ironwoodpharma.com

IRONWOOD PHARMACEUTICALS ANNOUNCES PARTICIPATION IN J.P. MORGAN BIOTECH CEO/CFO CONFERENCE CALL

CAMBRIDGE, Mass., May 26, 2010 — Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will participate in the J.P. Morgan Biotech: CEO/CFO Conference Call Series at 10:00 a.m. Eastern Time on Friday, May 28, 2010.

Conference call details are as follows:

- Live conference call (U.S.): (888) 889-1309
- Live conference call (outside the U.S.): (773) 756-0161
- Live passcode: BIOTECH
- Replay (U.S.): (866) 501-0089
- Replay (outside the U.S.): (203) 369-1817
- Replay passcode: 2597

A recording of the call will be available for telephone replay for one week following the call.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, Ironwood's GC-C agonist, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood is located in Cambridge, Mass.

SOURCE: Ironwood Pharmaceuticals, Inc.